Skip to content
Inciteful Med

Building Your Care Team

Last updated:

Treating acute myeloid leukemia (AML) requires a highly coordinated, multidisciplinary medical team at a specialized cancer center. High-volume academic centers offer critical resources like on-site stem cell transplants, advanced genetic testing, and access to life-saving clinical trials.

Key Takeaways

  • • Patients treated for AML at specialized, high-volume academic cancer centers often experience better survival outcomes.
  • • A comprehensive AML care team includes hematologist-oncologists, transplant specialists, clinical pharmacists, and social workers.
  • • Specialized centers offer crucial in-house services like advanced genetic testing and allogeneic stem cell transplants.
  • • Preparing your pathology reports, marrow slides, and genetic test results is essential for your first oncology consultation.

An AML diagnosis is an emergency that requires a sophisticated, highly coordinated response. Because AML is a complex disease driven by specific genetic mutations, the quality of your care team—and where they practice—can significantly impact your survival [1][2]. Building the right team early ensures that you have access to the most advanced testing, specialized treatments, and potentially life-saving clinical trials [3][4].

Why specialized centers matter

Research shows that patients treated at specialized, high-volume academic cancer centers often have better outcomes than those treated at smaller community hospitals [1]. In one study, patients receiving intensive treatment at specialized centers had a median survival of 31 months, compared to just 18 months for those treated at non-specialized centers [1].

These centers are critical because they offer:

  • On-Site Transplant Capabilities: Many AML patients will eventually need an allogeneic stem cell transplant (allo-HSCT)—a complex procedure that replaces your marrow with healthy donor cells [5][6]. Centers with on-site transplant teams can integrate this option into your plan from day one [7].
  • Advanced Genetic Testing: Specialized labs can perform Next-Generation Sequencing (NGS) and Flow Cytometry in-house, which is essential for identifying your leukemia’s “genetic fingerprint” and monitoring for any remaining cancer cells (MRD) [8][2].
  • Clinical Trials: Access to experimental drugs can be vital, especially if the leukemia is resistant to standard chemotherapy [9][4].

Your Multidisciplinary Team

Managing AML requires more than just one doctor. You will likely work with a multidisciplinary team of professionals, each focusing on a different aspect of your health [10][11]:

  • Hematologist-Oncologist: A doctor who specializes in blood cancers and will lead your overall treatment [10].
  • Transplant Specialist: A doctor focused specifically on the logistics and care involved in stem cell transplantation [12].
  • Advanced Practice Providers (NPs and PAs): These specialists often handle your day-to-day care, symptom management, and lab monitoring [13].
  • Social Workers and Case Managers: Essential for helping you navigate the emotional, financial, and logistical burdens of treatment [11].
  • Clinical Pharmacists: Specialized experts who ensure your chemotherapy and supportive medications (like anti-nausea or anti-fungal drugs) are managed safely [10].

Preparing for Your First Visit

Your first consultation is a critical step in establishing your “roadmap” for treatment. To make the most of this visit, you should arrive prepared with specific information [14][2]:

Your “First Visit Checklist”

  • Pathology Reports: Bring copies of your initial bone marrow biopsy and aspiration results [8][15].
  • Genetic Results: Ensure you have the results for Cytogenetics (Karyotyping) and Molecular Testing (NGS) [2][16].
  • Treatment Summary: If you have already started treatment (such as “7+3” or Venetoclax), bring a clear list of the drugs given and the dates they started [14].
  • Marrow Slides: If you are seeking a second opinion, the new center will often want to review your original bone marrow slides and blocks. You may need to request that these be mailed from the original hospital [8][15].
  • Medication List: Include all current prescriptions, vitamins, and over-the-counter supplements, as these can interact with leukemia treatments [17].

By gathering these items and seeking care at a center of excellence, you are taking active steps to ensure your treatment is as precise and effective as possible [2][3].

Frequently Asked Questions

Why should I seek treatment for AML at a specialized cancer center?
Specialized academic cancer centers often have better outcomes for AML patients because they offer high-volume experience, on-site stem cell transplant capabilities, and access to advanced genetic testing and clinical trials.
Who will be on my multidisciplinary AML care team?
Your team will typically be led by a hematologist-oncologist and may include transplant specialists, advanced practice providers, clinical pharmacists, and social workers. Each member focuses on different aspects of your treatment and recovery.
What should I bring to my first oncology appointment for AML?
You should bring your pathology reports, bone marrow slides, cytogenetic and molecular testing results, a complete medication list, and a summary of any treatments you have already started.
What is the role of a transplant specialist in AML treatment?
A transplant specialist manages the complex process of an allogeneic stem cell transplant, a procedure many AML patients eventually need to replace diseased bone marrow with healthy donor cells.
Why is advanced genetic testing important for AML care?
Advanced tests like Next-Generation Sequencing (NGS) and flow cytometry identify the unique genetic mutations driving your leukemia, which helps your doctors choose the most effective targeted treatments and monitor for remaining cancer cells.

Questions for Your Doctor

  • • How many new AML cases do you and this center treat each year?
  • • Is there an on-site allogeneic stem cell transplant program, and how closely do the leukemia and transplant teams work together?
  • • Who are the members of the multidisciplinary team (such as social workers, pharmacists, or nutritionists) that will be involved in my care?
  • • What clinical trials are available at this center for my specific genetic subtype of AML?
  • • What is the process for monitoring my 'MRD' (measurable residual disease), and does this center perform that testing in-house?

Questions for You

  • • Do I have a primary caregiver or support person who can attend these appointments with me and help track information?
  • • Have I organized my records into a single folder, including pathology reports, genetic testing (NGS), and a list of all current medications?
  • • What are my biggest concerns right now—is it the long-term prognosis, the side effects of treatment, or the logistical challenges like travel and cost?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Determinants of Outcomes for Acute Myeloid Leukemia Patients Treated in a Community-Based Specialized Versus Non-Specialized Hospital Setting.

    Battiwalla M, Chao JH, Cox T, et al.

    Clinical hematology international 2024; (6(4)):43-52 doi:10.46989/001c.124273.

    PMID: 39417014
  2. 2

    Comparative Analysis of AML Classification Systems: Evaluating the WHO, ICC, and ELN Frameworks and Their Distinctions.

    Salman H

    Cancers 2024; (16(16)) doi:10.3390/cancers16162915.

    PMID: 39199685
  3. 3

    Ambulatory Hematopoietic Stem Cell Transplantation in Young Adults with Acute Myeloid Leukemia Treated with Venetoclax and Low Doses of Cytarabine: Report of Two Cases.

    Flores-Jiménez JA, Pimentel-Morales MA, González-Ramella O, et al.

    Journal of adolescent and young adult oncology 2019; (8(4)):481-483 doi:10.1089/jayao.2018.0137.

    PMID: 30835153
  4. 4

    Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial.

    Pigneux A, Béné MC, Salmi LR, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(32)):3203-3210 doi:10.1200/JCO.2018.78.7366.

    PMID: 30260758
  5. 5

    Newly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder.

    Yiğit Kaya S, Askin AE, Bektas S, et al.

    Leukemia research reports 2023; (19()):100369 doi:10.1016/j.lrr.2023.100369.

    PMID: 37213444
  6. 6

    Evolution of Allogeneic Stem Cell Transplantation: Main Focus on AML.

    Inoue Y, Cioccio J, Mineishi S, Minagawa K

    Cells 2025; (14(8)) doi:10.3390/cells14080572.

    PMID: 40277898
  7. 7

    [Venetoclax plus azacitidine as successful bridging therapy to second transplantation for post-transplant extramedullary relapse of acute myeloid leukemia].

    Endo T, Takahashi H, Namiki T, et al.

    [Rinsho ketsueki] The Japanese journal of clinical hematology 2026; (67(2)):124-128 doi:10.11406/rinketsu.67.124.

    PMID: 41780956
  8. 8

    Novel Tools for Diagnosis and Monitoring of AML.

    Guijarro F, Garrote M, Villamor N, et al.

    Current oncology (Toronto, Ont.) 2023; (30(6)):5201-5213 doi:10.3390/curroncol30060395.

    PMID: 37366878
  9. 9

    Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges.

    Alfayez M, Borthakur G

    Expert review of hematology 2018; (11(5)):373-389 doi:10.1080/17474086.2018.1459184.

    PMID: 29589969
  10. 10

    Alternatives to intensive treatment in patients with AML.

    Himmelstein G, Mascarenhas J, Marcellino BK

    Clinical advances in hematology & oncology : H&O 2021; (19(8)):526-535.

    PMID: 34411072
  11. 11

    Sickle Cell Anomaly Meets Leukemic Challenge: A Case Report.

    Mandviya SH, Hingway S, Wanjari M, et al.

    Cureus 2024; (16(3)):e57089 doi:10.7759/cureus.57089.

    PMID: 38681383
  12. 12

    T Lymphocyte Reconstitution in Acute Leukemia Patients After Allogeneic Stem Cell Transplantation: A Single Center Experience (2016-2023).

    Nguyen KB, Nguyen NTH, Vo BTT, Nguyen TH

    Transplantation proceedings 2026; (58(1)):202-206 doi:10.1016/j.transproceed.2025.11.014.

    PMID: 41507002
  13. 13

    Economic burden in US patients with newly diagnosed acute myeloid leukemia receiving intensive induction chemotherapy.

    Huggar D, Knoth RL, Copher R, et al.

    Future oncology (London, England) 2022; (18(32)):3609-3621 doi:10.2217/fon-2022-0706.

    PMID: 36305495
  14. 14

    Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML.

    Tsai CH, Tang JL, Tien FM, et al.

    Blood advances 2021; (5(10)):2456-2466 doi:10.1182/bloodadvances.2020003738.

    PMID: 33999144
  15. 15

    Current status and trends in the diagnostics of AML and MDS.

    Shumilov E, Flach J, Kohlmann A, et al.

    Blood reviews 2018; (32(6)):508-519 doi:10.1016/j.blre.2018.04.008.

    PMID: 29728319
  16. 16

    Prognostic impact of next-generation sequencing on myelodysplastic syndrome: A single-center experience.

    Bülbül H, Kaya ÖÖ, Karadağ FK, et al.

    Medicine 2024; (103(41)):e39909 doi:10.1097/MD.0000000000039909.

    PMID: 39465815
  17. 17

    Side effects from acute myeloid leukemia treatment: results from a national survey.

    Crossnohere NL, Richardson DR, Reinhart C, et al.

    Current medical research and opinion 2019; (35(11)):1965-1970 doi:10.1080/03007995.2019.1631149.

    PMID: 31188058

This page provides educational information on building a care team for acute myeloid leukemia. It does not replace professional medical advice from your hematologist-oncologist.

Stay up to date

Get notified when new research about Acute myeloid leukemia is published.

No spam. Unsubscribe anytime.